The local community doctor has an important role in recognizing, diagnosing, and managing myelofibrosis, said Naveen Pemmaraju, MD, associate professor in the Department of Leukemia at MD Anderson Cancer Center.
The local community doctor has an important role in recognizing, diagnosing, and managing myelofibrosis, said Naveen Pemmaraju, MD, associate professor in the Department of Leukemia at MD Anderson Cancer Center.
Transcript
Do primary care physicians frequently play a role in the diagnosis of myelofibrosis or specialist referral?
Myelofibrosis is often thought of as fairly rare blood cancer, possibly something on the order of 4 to 6 patients out of every 100,000 diagnosed in the United States. However, as with any rare or less common blood cancer, there might be more patients walking around that just haven’t been diagnosed. So, with myelofibrosis and [myeloproliferative neoplasms] in general, the community practice provider plays a very important role in both the recognition, diagnosis, and management.
Of course, I work at an academic center, and I always encourage any patient and any doctor to seek a second or even a third opinion and to be referred to a major academic center. But let’s remember that in rare diseases it’s only rare to others. But when you have that disease, it’s your disease and your body. And so, yes, I do encourage that the local community doctor has a very important role to recognize this disease, diagnose, and we can comanage together. So, that’s the model that I favor: having multiple doctors involved; academic physicians, community physicians working hand in hand for maximal patient care for patients with myelofibrosis.
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
ACC017 Showed Safety, Tolerability When Used as Antiretroviral Therapy
September 4th 2025New abstracts from the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025 found that ACC017 showed promise in its use as an antiretroviral therapy.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
ACC017 Showed Safety, Tolerability When Used as Antiretroviral Therapy
September 4th 2025New abstracts from the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025 found that ACC017 showed promise in its use as an antiretroviral therapy.
Read More
2 Commerce Drive
Cranbury, NJ 08512